conferenceseries.com

7th World Congress on

Healthcare & Technologies

September 26-27, 2016 London, UK

MYOBLAST TRANSFER THERAPIES ALLEVIATE DISEASE CONDITIONS IN HEREDITARY MUSCULAR DYSTROPHIES, CARDIOMYOPATHIES, TYPE-II DIABETES, CANCER AND AGING

Peter K. Law^{ab} °Cell Therapy Institute, China ^bHuazhong University of Science & Technology, China

Myoblast implantation is a unique, patented technology of muscle regeneration being tested in Phase III clinical trials of muscular dystrophy, ischemic cardiomyopathy, Phase II trial of cancer, and Phase I trial of Type II diabetes. Differentiated and committed, myoblasts are not stem cells. Implanted myoblasts fuse spontaneously among themselves, replenishing genetically normal myofibers. They also fuse with genetically abnormal myofibers of patients having muscular dystrophy, cardiomyopathy, or Type II diabetes, transferring their nuclei containing the normal human genome to provide long-term expression of the missing gene products. They develop to become cardiomyocytes in the infracted myocardium. Myoblasts transduced with VEGF165 or Angiopoietin-1 allows concomitant regeneration of blood capillaries and myofibers. These are potent biologic for treating heart failure, ischemic cardiomyopathy, diabetic ischemia, erectile dysfunction, and baldness. Human myoblasts induced cancer cell apoptosis in co-cultures, and in solid tumors in nude mice and cancer patients. Histologic study demonstrated significant reductions in tumor sizes and the number of surviving tumor cells. Cancer cell proliferation was interrupted. Myoblasts, because of their small size, spindle shape, and resilience, can grow within wrinkles and on skin surfaces, thus enhancing the color, luster and texture of the skin "plated" with them. They can be injected subcutaneously as a cellular filler to reduce wrinkles. Intramuscular injection of myoblasts can augment the size, shape, consistency, tone and strength of muscle groups, improving the lines, contours and vitality to sculpt a youthful appearance. This technology has great social, economic values in treating hereditary, fatal and debilitating disease conditions.

peter.celltherapy@yahoo.com

RESEARCH ADVANCE IN THE EFFICACY AND MECHANISM OF QING FEI XIAO YAN WAN FOR THE TREATMENT OF RESPIRATORY DISEASES

Junying Ding^a and Qingquan Liu^{ab}

^aBeijing Research Institute of Traditional Chinese Medicine, China ^bCapital Medical University, china

Qing Fei Xiao Yan Wan had been incorporated into the existing "Chinese Pharmacopoeia", protected by patents. The manufacturing process of it was scientific and its compatibility was reasonable. It was also shown by clinical trials that the efficacy is exact. Clinical trials and experiment studies had confirmed the efficacy and some mechanism for the treatment of respiratory diseases. Combined with the experimental results, the other prospect application was further discussed.

18211197728@163.com